Compare McKesson Corporation (MCK) vs Sea Limited (SE) Price & Performance

McKesson (MCK) trades at $930.25, up 0.93% with strong bullish momentum after recent earnings beats and positive news flow. The stock shows robust technical strength with moving averages signaling bullish alignment and price trading near resistance at $926. Fundamentally, revenue growth accelerated to $359.1 billion in 2025 with consistent profitability, though thin margins remain a characteristic of the distribution business model. Recent catalyst includes the CVS Health partnership extension through 2032, reinforcing long-term revenue visibility.

Outlook remains positive with 81% analyst buy ratings and $956.43 consensus target suggesting 2.8% upside. Key opportunities include oncology/GLP-1 growth drivers and operational efficiency gains, while risks center on drug pricing pressure, policy uncertainty, and competitive threats. The company's improved cash flow generation and debt reduction support financial stability amid sector headwinds.

Sea Limited (SE) trades at $92.89, down 3.77% on the day, with bearish technical signals dominating despite strong fundamental growth. The company reported robust revenue growth from $22.94B in 2025 to $27.7B projected for 2026, with net income reaching $1.58B. Recent earnings show mixed results with Q4 2025 missing expectations but Q1 and Q2 2026 beating estimates. Analyst sentiment remains overwhelmingly positive with 70% buy ratings and a $153.67 consensus price target representing 65% upside potential.

The investment case hinges on Sea's continued e-commerce and fintech expansion, though the stock faces near-term technical pressure. Key risks include margin compression concerns and insider selling activity. With strong cash flow generation improving from negative $3.2B in 2022 to positive $2.34B in 2025, the fundamentals support long-term growth despite current bearish technical indicators.